Perimenopause Onset Symptoms: Causes, Drugs That Trigger Them, and Treatments That Work

When does perimenopause start?

Menopause is reached after 12 months in a row with no period. Perimenopause is the time before that, when hormone levels change and periods become irregular [9][1]. The transition usually begins when a woman is in her 40s, most often the mid-to-late 40s, although some women notice symptoms in their mid-to-late 30s [1]. It lasts about four years on average and can last up to 10 years [1].

What actually marks the onset?

STRAW+10, the standard staging system, defines the start of the transition by bleeding pattern rather than by hormone levels, and it applies regardless of age, ethnicity or body size [10][7].

• Early transition (stage -2): cycle lengths that differ by 7 or more days from one cycle to the next, recurring within 10 cycles [7].
• Late transition (stage -1): 60 days or more without a period [7].
• The final menstrual period is confirmed only in hindsight, after 12 months without bleeding [7].

In STRAW+10 terms, perimenopause runs from stage -2 through the 12 months after the final period [7]. Hot flashes are likely in late transition and most likely in the first two years after the final period; vaginal dryness becomes more common later, in stage +2 [7].

Which symptoms come first?

Hot flashes and night sweats. These are the classic early symptoms. In SWAN, a study of 3,302 women at seven US sites, the median total duration of frequent hot flashes or night sweats was 7.4 years, and the median persistence after the final menstrual period was 4.5 years [8]. Women who first reported frequent symptoms while premenopausal or in early perimenopause had the longest course, a median of more than 11.8 years, and Black women reported the longest total duration at a median of 10.1 years [8]. The FDA cites a 2021 study that put the prevalence of moderate-to-severe hot flashes in women aged 45 to 65 at about 34 percent [11].

Sleep. In a SWAN community survey of 12,603 women aged 40 to 55, 38 percent reported difficulty sleeping in the previous two weeks; rates were highest in late perimenopause (45.4 percent) and after surgical menopause (47.6 percent), and menopausal stage remained associated with sleep difficulty after accounting for other factors [12].

Mood. In an 8-year within-woman study of women with no history of depression, high depression scores were more than four times as likely during the menopausal transition as when the same women were premenopausal (odds ratio 4.29, 95% CI 2.39 to 7.72), and a diagnosed depressive disorder was 2.5 times as likely (odds ratio 2.50, 95% CI 1.25 to 5.02) [13].

Vaginal and urinary symptoms. Vaginal dryness becomes more common in stage +2 [7], and without treatment genital and urinary symptoms, including repeated urinary tract infections, may worsen over time [1]. Only about 25 percent of women with vaginal atrophy in Western countries seek medical help for it [14].

What can bring on early menopause, and which medicines interact with treatment?

Surgery to remove both ovaries causes menopause right away [1]. Chemotherapy or hormone therapy used to treat breast cancer may cause menopause to start earlier than usual, and smoking, a family history of early menopause and certain health conditions are other reasons for early or premature menopause [9]. Menopause before age 45 is called early and before age 40 premature [9].

Tamoxifen and paroxetine. Paroxetine is a strong CYP2D6 inhibitor and lowers plasma levels of tamoxifen's active metabolite; the Brisdelle label says to consider avoiding their combined use [3]. Paroxetine can also raise levels of tricyclic antidepressants, risperidone, atomoxetine and free warfarin [3].

Drugs that change estrogen levels. Estrogens are partly metabolized by CYP3A4. Per the Premarin label, inducers such as St John's wort, phenobarbital, carbamazepine and rifampin may reduce estrogen concentrations, possibly reducing the therapeutic effect and changing the bleeding profile; inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise estrogen concentrations and cause side effects [16]. Estrogen labels also advise monitoring thyroid function in women on thyroid replacement therapy [17].

How is perimenopause diagnosed?

Usually from age, symptoms and menstrual changes. Blood hormone tests are not usually needed [1]. In STRAW+10, a quantitative FSH criterion applies only to late transition: a random FSH above 25 IU/L suggests stage -1 [7]. AMH, antral follicle count and inhibin B are supportive markers only, because the assays are not standardized [7]. A single FSH reading does not confirm menopause; 12 months without a period does [7]. Women without a uterus, or who have had endometrial ablation, cannot be staged by bleeding, and FSH should not be tested until at least 3 months after surgery [7].

What treatments work?

Hormone therapy

Hormone therapy remains the most effective treatment for hot flashes and night sweats and for genitourinary syndrome of menopause, and it has been shown to prevent bone loss and fracture [2]. For women younger than 60 or within 10 years of menopause onset with no contraindications, the benefit-risk ratio is favorable for bothersome symptoms and bone protection [2]. Risks differ by type, dose, duration, route, timing of initiation and whether a progestogen is used, and longer durations should be for documented indications such as persistent hot flashes, with periodic reevaluation [2].

The Premarin label says to start at 0.3 mg daily for moderate to severe hot flashes, use the lowest effective dose and reassess periodically [16]. The Divigel label adds that initiation should be considered in women under 60 or within 10 years of menopause onset [17]. A progestogen is added in women with a uterus to reduce the risk of endometrial hyperplasia and cancer; women without a uterus usually do not need one, although the Premarin label notes that some with a history of endometriosis may [16]. Progesterone capsules (Prometrium) are labeled for endometrial protection in women with a uterus taking conjugated estrogens [19]. Duavee pairs conjugated estrogens with bazedoxifene, an estrogen agonist/antagonist used instead of a progestin, and is for women with a uterus [18].

Label status has been shifting. In November 2025 the FDA asked manufacturers to remove the cardiovascular disease, breast cancer and probable dementia statements from the boxed warnings; on 12 February 2026 it approved the first labeling changes, for six products, while retaining the endometrial cancer boxed warning for systemic estrogen-alone products and keeping cardiovascular and breast cancer warnings in Warnings and Precautions for systemic products [11][20][21]. Many labels still carry the older box; the Premarin oral label effective 4 June 2026 still has it [16].

The current oral Premarin label lists contraindications including undiagnosed abnormal genital bleeding, breast cancer or a history of it, estrogen-dependent neoplasia, thromboembolic disease, hepatic disease, thrombophilia, and prior anaphylaxis or angioedema to Premarin [16].

Route matters for clot risk. In a UK observational nested case-control study of 80,396 women with venous thromboembolism and 391,494 controls aged 40 to 79, oral hormone therapy was associated with an adjusted odds ratio of 1.58 (95% CI 1.52 to 1.64) versus no exposure, while transdermal preparations were not associated with venous thromboembolism risk [22].

Non-hormonal prescription drugs

Brisdelle (paroxetine mesylate) 7.5 mg once daily at bedtime is approved for moderate to severe hot flashes at a dose lower than the doses used for depression, and it is not approved for any psychiatric condition [3]. In two phase 3 trials with 591 women on paroxetine and 593 on placebo, it reduced weekly hot flash frequency compared with placebo at week 4 (P<0.0001 in both studies) and at week 12 (P=0.0090 and P=0.0001) [23]. It carries the SSRI boxed warning for suicidality and is contraindicated with MAOIs and within 14 days of them, with thioridazine and pimozide, and in pregnancy [3].

Veozah (fezolinetant) 45 mg once daily is a neurokinin 3 receptor antagonist approved in 2023 [4]. The week-12 reduction in daily hot flash frequency versus placebo was 2.6 per day (95% CI 1.7 to 3.4) in SKYLIGHT 1 (174 versus 175 women) and 2.5 per day (95% CI 1.5 to 3.6) in SKYLIGHT 2 (167 versus 167) [24][4]. It carries a boxed warning for liver injury. The label requires baseline liver tests, says not to start if ALT or AST is at least 2 times the upper limit of normal or bilirubin is at least 2 times that limit, and calls for testing monthly for the first three months, then at months 6 and 9 [4][15]. It is contraindicated in cirrhosis, severe renal impairment or end-stage renal disease, and with CYP1A2 inhibitors [4].

Lynkuet (elinzanetant) 120 mg, taken as two 60 mg capsules at bedtime, is a dual NK1 and NK3 receptor antagonist approved in October 2025 [5]. In the OASIS 1 and 2 trials, the week-12 reduction in moderate to severe hot flashes per 24 hours versus placebo was 3.22 and 3.24 respectively [25]. The label calls for baseline liver tests and a follow-up at three months, says to exclude pregnancy before starting, and advises contraception during treatment and for two weeks after stopping [5]. Nervous-system effects such as somnolence, fatigue, vertigo, dizziness and presyncope occurred in 11.9 percent of women on elinzanetant versus 3.5 percent on placebo across the three OASIS trials [5]. The Lynkuet label says to avoid strong CYP3A4 inhibitors and grapefruit; with a moderate CYP3A4 inhibitor, its dose is 60 mg once daily [5].

Other options

Gabapentin, other SSRIs and SNRIs, and oxybutynin are used for hot flashes but are not FDA-labeled for it. The Menopause Society's 2023 position statement recommended cognitive-behavioral therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant (Level I), oxybutynin (Levels I to II), and weight loss and stellate ganglion block (Levels II to III). It did not recommend paced respiration, supplements or herbal remedies [26]. That statement predates elinzanetant's approval, so elinzanetant is not part of it [26].

Gabapentin 300 mg three times daily lowered the hot flash score by 51 percent versus 26 percent on placebo over four weeks in a trial of 197 women (P<0.001); dizziness, unsteadiness and drowsiness were more common in the first week and returned to baseline by week 4 [27]. Extended-release oxybutynin 15 mg daily reduced moderate to severe hot flashes by 9.48 episodes per day versus 4.69 on placebo at week 12 in a trial of 73 versus 75 women, with dry mouth in 52.1 percent versus 5.3 percent [28].

Vaginal symptoms and compounded hormones

For bothersome genitourinary symptoms not relieved by over-the-counter products, low-dose vaginal estrogen, vaginal DHEA (prasterone) or oral ospemifene are recommended [2]. Osphena carries boxed warnings for endometrial cancer and cardiovascular disorders [29]. Compounded bioidentical hormones are not FDA-approved: the FDA says it has no evidence they are safe and effective and recommends FDA-approved therapy, and there are no FDA-approved estriol drugs [30]. ACOG advises that compounded bioidentical hormone therapy should not be prescribed routinely when FDA-approved formulations exist [31].

Warning signs

Vaginal bleeding after menopause is not normal [1]. Undiagnosed abnormal genital bleeding is also a contraindication to estrogen products [16]. Primary ovarian insufficiency is different from early menopause: periods may still occur, and pregnancy may still be possible [9].